Vision Engineering appoints Harry Curtis as Technical Director, joins Board

In his new role, Curtis will lead the formulation and execution of the company’s global technical strategy

Innovent Biologics’ OLN324 shows breakthrough results in vision disease study

The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred

GelMEDIX partners with Catalent to advance vision-restoring cell therapies

The biotechnology company will tap into Catalent’s expertise in induced pluripotent stem cells and advanced cell-therapy manufacturing

Merck restructures Human Health division for future growth

Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential

Jubilant Pharmova posts robust Q3, eyes Vision 2030 with sterile injectables drive

The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses

MHRA warns of extremely rare vision risk linked to semaglutide

Semaglutide—a glucagon?like peptide?1 receptor agonist (GLP-1RA) sold as Ozempic and Rybelsus for type 2 diabetes, and Wegovy for weight management and cardiovascular risk reduction

Arctic Vision expands global reach with acquisition of MDCO Technology’s ophthalmic device business

Functional Gut Clinic launches UK’s first boutique GI clinical trials division

Gastrointestinal conditions affect millions across the UK, yet research in the field has often been fragmented, slow, or under-resourced

Complement Therapeutics’ gene therapy gains FDA fast-track for vision loss treatment

CTx001 targets Geographic Atrophy (GA) secondary to Age-related Macular Degeneration

WHO and OneSight EssilorLuxottica partner to expand vision care in Karnataka

WHO’s global SPECS 2030 target to increase effective refractive error coverage by 40% by 2030